Wednesday, August 27th, 2025
Stock Profile: VIR
VIR Logo

Vir Biotechnology, Inc. (VIR)

Market: NASD | Currency: USD

Address: 1800 Owens Street

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements Show more




📈 Vir Biotechnology, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Vir Biotechnology, Inc.


DateReported EPS
2025-10-30 (estimated upcoming)-
2025-08-06-0.8
2025-05-07-0.88
2025-02-26-0.76
2024-10-31-1.56
2024-08-01-1.02
2024-05-02-0.48
2024-02-22-0.86
2023-11-02-1.22
2023-08-03-1.45
2023-05-04-1.06
2023-02-23-0.76
2022-11-031.3
2022-08-09-0.58
2022-05-053.85
2022-02-243.92
2021-11-040.82
2021-08-050.46
2021-05-06-1.32
2021-02-25-0.83
2020-11-10-0.67
2020-08-11-0.27
2020-05-12-0.71
2020-03-26-0.69
2019-11-19-4.6




📰 Related News & Research


No related articles found for "vir biotechnology".